SCHEMBL4507269

SCHEMBL4507269

CCN1C(=O)C(C)(C)c2cc3nc(-c4n[nH]c5cc(/C=C/c6ccccc6)ccc45)[nH]c3cc21

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 3/20 0.51
AURKB Q96GD4 3/20 0.51
CHEK1 O14757 7/20 0.40
CDK2 P24941 6/20 0.40
KDR P35968 3/20 0.40
SRC P12931 2/20 0.40
FLT3 P36888 2/20 0.40
GSK3B P49841 2/20 0.40
JAK2 O60674 6/20 0.39
TYK2 P29597 6/20 0.39
JAK3 P52333 6/20 0.39
JAK1 P23458 5/20 0.39
CDK4 P11802 4/20 0.39
CCNA2 P20248 4/20 0.39
CCND1 P24385 4/20 0.39
CCND3 P30281 4/20 0.39
BRD4 O60885 1/20 0.37
FGFR1 P11362 4/20 0.36
FLT1 P17948 4/20 0.36
ITK Q08881 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4507275 1.00 AURKA (0.51) AURKAAURKBCHEK1CDK2KDR
SCHEMBL4500978 0.96 AURKA (0.49) AURKAAURKBCHEK1CDK2KDR
SCHEMBL4500983 0.96 AURKA (0.49) AURKAAURKBCHEK1CDK2KDR
SCHEMBL4501399 0.93 AURKA (0.51) AURKAAURKBCHEK1CDK2KDR
SCHEMBL4504801 0.93 AURKA (0.51) AURKAAURKBCHEK1CDK2KDR
SCHEMBL4504808 0.93 AURKA (0.51) AURKAAURKBCHEK1CDK2KDR
SCHEMBL4501403 0.93 AURKA (0.51) AURKAAURKBCHEK1CDK2KDR
SCHEMBL4507231 0.92 AURKA (0.49) AURKAAURKBCHEK1CDK2KDR
SCHEMBL4507234 0.92 AURKA (0.49) AURKAAURKBCHEK1CDK2KDR
SCHEMBL4505049 0.91 AURKB (0.49) AURKAAURKBCHEK1CDK2KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090291968-A1 SUBSTITUTED INDAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS GEORGES GUY 2009-11-26 US claimed
US-20090291968-A1 SUBSTITUTED INDAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS GEORGES GUY 2009-11-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090291968-A1 SUBSTITUTED INDAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS CYP3A43, CYP3A5, CYP3A7 AURKA 1558/4885AURKB 2087/4885CHEK1 1412/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.